Pharmacological properties of bergapten: mechanistic and therapeutic aspects

Detalhes bibliográficos
Autor(a) principal: Quetglas-Llabrés, Maria Magdalena
Data de Publicação: 2022
Outros Autores: Quispe, Cristina, Herrera-Bravo, Jesús, Catarino, Marcelo D., Pereira, Olívia R., Cardoso, Susana M., Dua, Kamal, Chellappan, Dinesh Kumar, Pabreja, Kavita, Satija, Saurabh, Mehta, Meenu, Sureda, Antoni, Martorell, Miquel, Satmbekova, Dinara, Yeskaliyeva, Balakyz, Sharifi-Rad, Javad, Rasool, Naeem, Butnariu, Monica, Bagiu, Iulia Cristina, Bagiu, Radu Vasile, Calina, Daniela, Cho, William C.
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10198/25534
Resumo: Bergapten (BP) or 5-methoxypsoralen (5-MOP) is a furocoumarin compound mainly found in bergamot essential oil but also in other citrus essential oils and grapefruit juice. This compound presents antibacterial, anti-inflammatory, hypolipemic, and anticancer effects and is successfully used as a photosensitizing agent. The present review focuses on the research evidence related to the therapeutic properties of bergapten collected in recent years. Many preclinical and in vitro studies have been evidenced the therapeutic action of BP; however, few clinical trials have been carried out to evaluate its efficacy. These clinical trials with BP are mainly focused on patients suffering from skin disorders such as psoriasis or vitiligo. In these trials, the administration of BP (oral or topical) combined with UV irradiation induces relevant lesion clearance rates. In addition, beneficial effects of bergamot extract were also observed in patients with altered serum lipid profiles and in people with nonalcoholic fatty liver. On the contrary, there are no clinical trials that investigate the possible effects on cancer. Although the bioavailability of BP is lower than that of its 8-methoxypsoralen (8-MOP) isomer, it has fewer side effects allowing higher concentrations to be administered. In conclusion, although the use of BP has therapeutic applications on skin disorders as a sensitizing agent and as components of bergamot extract as hypolipemic therapy, more trials are necessary to define the doses and treatment guidelines and its usefulness against other pathologies such as cancer or bacterial infections.
id RCAP_b30412d95416f27706e3c08bbe4a66b5
oai_identifier_str oai:bibliotecadigital.ipb.pt:10198/25534
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str
spelling Pharmacological properties of bergapten: mechanistic and therapeutic aspects5-MethoxypsoralenHumansMethoxsalenOlisVolatilePhotosensitizing agentsPlant extractsUltraviolet raysBergapten (BP) or 5-methoxypsoralen (5-MOP) is a furocoumarin compound mainly found in bergamot essential oil but also in other citrus essential oils and grapefruit juice. This compound presents antibacterial, anti-inflammatory, hypolipemic, and anticancer effects and is successfully used as a photosensitizing agent. The present review focuses on the research evidence related to the therapeutic properties of bergapten collected in recent years. Many preclinical and in vitro studies have been evidenced the therapeutic action of BP; however, few clinical trials have been carried out to evaluate its efficacy. These clinical trials with BP are mainly focused on patients suffering from skin disorders such as psoriasis or vitiligo. In these trials, the administration of BP (oral or topical) combined with UV irradiation induces relevant lesion clearance rates. In addition, beneficial effects of bergamot extract were also observed in patients with altered serum lipid profiles and in people with nonalcoholic fatty liver. On the contrary, there are no clinical trials that investigate the possible effects on cancer. Although the bioavailability of BP is lower than that of its 8-methoxypsoralen (8-MOP) isomer, it has fewer side effects allowing higher concentrations to be administered. In conclusion, although the use of BP has therapeutic applications on skin disorders as a sensitizing agent and as components of bergamot extract as hypolipemic therapy, more trials are necessary to define the doses and treatment guidelines and its usefulness against other pathologies such as cancer or bacterial infections.HindawiBiblioteca Digital do IPBQuetglas-Llabrés, Maria MagdalenaQuispe, CristinaHerrera-Bravo, JesúsCatarino, Marcelo D.Pereira, Olívia R.Cardoso, Susana M.Dua, KamalChellappan, Dinesh KumarPabreja, KavitaSatija, SaurabhMehta, MeenuSureda, AntoniMartorell, MiquelSatmbekova, DinaraYeskaliyeva, BalakyzSharifi-Rad, JavadRasool, NaeemButnariu, MonicaBagiu, Iulia CristinaBagiu, Radu VasileCalina, DanielaCho, William C.2022-05-24T11:20:20Z20222022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10198/25534porQuetglas-Llabrés, Maria Magdalena; Quispe, Cristina; Herrera-Bravo, Jesús; Catarino, Marcelo D.; Pereira, Olívia R.; Cardoso, Susana M.; Dua, Kamal; Chellappan, Dinesh Kumar; Pabreja, Kavita; Satija, Saurabh; Mehta, Meenu; Sureda, Antoni; Martorell, Miquel; Satmbekova, Dinara; Yeskaliyeva, Balakyz; Sharifi-Rad, Javad; Rasool, Naeem; Butnariu, Monica; Bagiu, Iulia Cristina; Bagiu, Radu Vasile; Calina, Daniela; Cho, William C. (2022). Pharmacological properties of bergapten: mechanistic and therapeutic aspects. Oxidative Medicine and Cellular Longevity. ISSN 1942-0900. p. 1-101942-090010.1155/2022/86152421942-0994info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-04-12T01:27:46ZPortal AgregadorONG
dc.title.none.fl_str_mv Pharmacological properties of bergapten: mechanistic and therapeutic aspects
title Pharmacological properties of bergapten: mechanistic and therapeutic aspects
spellingShingle Pharmacological properties of bergapten: mechanistic and therapeutic aspects
Quetglas-Llabrés, Maria Magdalena
5-Methoxypsoralen
Humans
Methoxsalen
Olis
Volatile
Photosensitizing agents
Plant extracts
Ultraviolet rays
title_short Pharmacological properties of bergapten: mechanistic and therapeutic aspects
title_full Pharmacological properties of bergapten: mechanistic and therapeutic aspects
title_fullStr Pharmacological properties of bergapten: mechanistic and therapeutic aspects
title_full_unstemmed Pharmacological properties of bergapten: mechanistic and therapeutic aspects
title_sort Pharmacological properties of bergapten: mechanistic and therapeutic aspects
author Quetglas-Llabrés, Maria Magdalena
author_facet Quetglas-Llabrés, Maria Magdalena
Quispe, Cristina
Herrera-Bravo, Jesús
Catarino, Marcelo D.
Pereira, Olívia R.
Cardoso, Susana M.
Dua, Kamal
Chellappan, Dinesh Kumar
Pabreja, Kavita
Satija, Saurabh
Mehta, Meenu
Sureda, Antoni
Martorell, Miquel
Satmbekova, Dinara
Yeskaliyeva, Balakyz
Sharifi-Rad, Javad
Rasool, Naeem
Butnariu, Monica
Bagiu, Iulia Cristina
Bagiu, Radu Vasile
Calina, Daniela
Cho, William C.
author_role author
author2 Quispe, Cristina
Herrera-Bravo, Jesús
Catarino, Marcelo D.
Pereira, Olívia R.
Cardoso, Susana M.
Dua, Kamal
Chellappan, Dinesh Kumar
Pabreja, Kavita
Satija, Saurabh
Mehta, Meenu
Sureda, Antoni
Martorell, Miquel
Satmbekova, Dinara
Yeskaliyeva, Balakyz
Sharifi-Rad, Javad
Rasool, Naeem
Butnariu, Monica
Bagiu, Iulia Cristina
Bagiu, Radu Vasile
Calina, Daniela
Cho, William C.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Biblioteca Digital do IPB
dc.contributor.author.fl_str_mv Quetglas-Llabrés, Maria Magdalena
Quispe, Cristina
Herrera-Bravo, Jesús
Catarino, Marcelo D.
Pereira, Olívia R.
Cardoso, Susana M.
Dua, Kamal
Chellappan, Dinesh Kumar
Pabreja, Kavita
Satija, Saurabh
Mehta, Meenu
Sureda, Antoni
Martorell, Miquel
Satmbekova, Dinara
Yeskaliyeva, Balakyz
Sharifi-Rad, Javad
Rasool, Naeem
Butnariu, Monica
Bagiu, Iulia Cristina
Bagiu, Radu Vasile
Calina, Daniela
Cho, William C.
dc.subject.por.fl_str_mv 5-Methoxypsoralen
Humans
Methoxsalen
Olis
Volatile
Photosensitizing agents
Plant extracts
Ultraviolet rays
topic 5-Methoxypsoralen
Humans
Methoxsalen
Olis
Volatile
Photosensitizing agents
Plant extracts
Ultraviolet rays
description Bergapten (BP) or 5-methoxypsoralen (5-MOP) is a furocoumarin compound mainly found in bergamot essential oil but also in other citrus essential oils and grapefruit juice. This compound presents antibacterial, anti-inflammatory, hypolipemic, and anticancer effects and is successfully used as a photosensitizing agent. The present review focuses on the research evidence related to the therapeutic properties of bergapten collected in recent years. Many preclinical and in vitro studies have been evidenced the therapeutic action of BP; however, few clinical trials have been carried out to evaluate its efficacy. These clinical trials with BP are mainly focused on patients suffering from skin disorders such as psoriasis or vitiligo. In these trials, the administration of BP (oral or topical) combined with UV irradiation induces relevant lesion clearance rates. In addition, beneficial effects of bergamot extract were also observed in patients with altered serum lipid profiles and in people with nonalcoholic fatty liver. On the contrary, there are no clinical trials that investigate the possible effects on cancer. Although the bioavailability of BP is lower than that of its 8-methoxypsoralen (8-MOP) isomer, it has fewer side effects allowing higher concentrations to be administered. In conclusion, although the use of BP has therapeutic applications on skin disorders as a sensitizing agent and as components of bergamot extract as hypolipemic therapy, more trials are necessary to define the doses and treatment guidelines and its usefulness against other pathologies such as cancer or bacterial infections.
publishDate 2022
dc.date.none.fl_str_mv 2022-05-24T11:20:20Z
2022
2022-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10198/25534
url http://hdl.handle.net/10198/25534
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Quetglas-Llabrés, Maria Magdalena; Quispe, Cristina; Herrera-Bravo, Jesús; Catarino, Marcelo D.; Pereira, Olívia R.; Cardoso, Susana M.; Dua, Kamal; Chellappan, Dinesh Kumar; Pabreja, Kavita; Satija, Saurabh; Mehta, Meenu; Sureda, Antoni; Martorell, Miquel; Satmbekova, Dinara; Yeskaliyeva, Balakyz; Sharifi-Rad, Javad; Rasool, Naeem; Butnariu, Monica; Bagiu, Iulia Cristina; Bagiu, Radu Vasile; Calina, Daniela; Cho, William C. (2022). Pharmacological properties of bergapten: mechanistic and therapeutic aspects. Oxidative Medicine and Cellular Longevity. ISSN 1942-0900. p. 1-10
1942-0900
10.1155/2022/8615242
1942-0994
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hindawi
publisher.none.fl_str_mv Hindawi
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1777301915876458496